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Summary
 
Pott’s disease (spinal tuberculosis), a condition characterized by massive resorption of the spinal
vertebrae, is one of the most striking pathologies resulting from local infection with 
 
Mycobacte-
rium tuberculosis
 
 (Mt; Boachie-Adjei, O., and R.G. Squillante. 1996. 
 
Orthop. Clin. North Am.
 
27:95–103). The pathogenesis of Pott’s disease is not established. Here we report for the first
time that a protein, identified by a monoclonal antibody to be the Mt heat shock protein
(Baird, P.N., L.M. Hall, and A.R.M. Coates. 1989. 
 
J. Gen. Microbiol.
 
 135:931–939) chaperonin
(cpn) 10, is responsible for the osteolytic activity of this bacterium. Recombinant Mt cpn10 is a
potent stimulator of bone resorption in bone explant cultures and induces osteoclast recruit-
ment, while inhibiting the proliferation of an osteoblast bone–forming cell line. Furthermore,
we have found that synthetic peptides corresponding to sequences within the flexible loop and
sequence 65–70 of Mt cpn10 may comprise a single conformational unit which encompasses its
potent bone-resorbing activity. Our findings suggest that Mt cpn10 may be a valuable pharma-
cological target for the clinical therapy of vertebral tuberculosis and possibly other bone dis-
eases.
 
T
 
uberculosis is epidemic, accounting for 7% of the an-
nual worldwide death toll (1). Tuberculous infections
of bone, particularly of the spinal vertebrae (Pott’s disease),
are still common in the third world (2). It is not known
how 
 
Mycobacterium tuberculosis
 
 (Mt)
 
1
 
 infections of bone
cause bone breakdown. Healthy bone is maintained by a
dynamic equilibrium between the mesenchymal bone ma-
trix–forming osteoblast cell lineage and the myeloid bone–
resorbing osteoclast cell lineage (3). Mt infection of the
spine obviously alters this dynamic equilibrium, resulting in
the net loss of the extracellular matrix of vertebral bone and
collapse of the vertebrae. Whether this loss of bone matrix
is the result of the direct action of components of Mt, for
example, the LPS-like cell surface molecule lipoarabi-
nomannan (LAM) (4), on bone cells, or an indirect activa-
tion of inflammatory cells leading to bone cell activation, is
not established. Evidence is appearing to suggest that mo-
lecular chaperones have biological actions in addition to
their intracellular protein–folding activity (5). For example,
chaperonin (cpn)10 has been found to be an essential
growth and immunosuppressive factor in early pregnancy
(6), and cpn60 induces cytokine synthesis (7) and resorp-
tion of bone (8).
In this study we have established that the bone resorbing
activity of Mt is due to cpn10 which is as active as the most
potent osteolytic cytokine, IL-1 (9, 10). Mt cpn10 also ap-
pears to induce the recruitment of osteoclasts in calvaria,
and it is notable that calvarial bone resorption induced by
this cpn can be completely blocked by the osteoclast-inhib-
iting hormone, calcitonin (11). Mt cpn10 was also found to
inhibit the proliferation of cultured osteoblasts.
 
1
 
Abbreviations used in this paper:
 
 cpn, chaperonin; LAM, lipoarabinoman-
nan; Mt, 
 
Mycobacterium tuberculosis
 
.
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Using a series of NH
 
2
 
- and COOH-terminal truncated
peptides, we have identified sites in Mt cpn10 responsible
for the osteolytic activity of this molecular chaperone. We
have identified the flexible loop of Mt cpn10 and the se-
quence 65–70 as regions most probably responsible for the
bone-modulating bioactivity of this molecule.
 
Materials and Methods
 
Mycobacterial Sonicate.
 
The sonicate was prepared by sonicat-
ing a suspension of viable virulent Mt (strain H37Rv) at 4
 
8
 
C for 1
min intervals, followed by a 1 min rest period, for a total period
of 1 h. The sonicated material was then centrifuged at 100,000 
 
g
 
for 1 h, and the supernatant was filtered through a 0.22-
 
m
 
m
membrane filter.
 
mAbs.
 
Both the mAb to Mt cpn10 (SA12; 12) and the mAb
to Mt cpn60 (TB78; reference 13) were obtained from murine
ascites in a sufficiently high titer to bind to Mt cpn10 or cpn60 at
the dilutions used in this study. SA12 is specific for mycobacterial
cpn10 and TB78 is specific for mycobacterial cpn60. Neither of
these mAbs are cross-reactive with any other Mt protein (14).
The mAb to LAM (CS-35) of isotype IgG3 was obtained from
concentrated tissue culture supernatant with a titer of 1:2,000 by
Western blot analysis (Belisle, J.T., personal communication).
CS-35 was raised against 
 
Mycobacterium leprae
 
 LAM and is cross-
reactive with Mt LAM at a dilution of 1:1,000 by Western blot
analysis (15). CS-35 was used at a 1:1,000 dilution in the bone re-
sorption assay.
 
Mt cpn10 Peptides.
 
r-Mt cpn10 was expressed in 
 
Escherichia
coli
 
 and purified by reversed-phase HPLC to 
 
.
 
97% purity as pre-
viously described (16). The synthetic peptide fragments were pre-
pared and purified by isoelectric focusing and by reversed phase
HPLC to 
 
.
 
95% purity as previously described (17). Before addi-
tion to the bone explants, r-Mt cpn10 was passed down a Poly-
myxin B–agarose column (Detoxigel column; Pierce, Rockford,
IL) to remove any contaminating LPS. The composition of the
peptides was confirmed by amino acid analysis and mass spectros-
copy. All peptides were tested for LPS using the limulus amoe-
bocyte lysate assay (Whittaker M.A. Bioproducts, Inc., Walkers-
ville, MD). All peptides tested negative, indicating the presence
of 
 
,
 
0.03 endotoxin U LPS.
 
Calcium Release and Osteoclast Recruitment in Murine Calvaria.
 
The calvarial bone resorption assay was performed as described
(18). In brief, calvaria were removed from 5-d-old MF1 mice,
adherent connective tissue was dissected away, and the calvarial
bone was halved, with each half being cultured separately on
stainless steel grids. Calvaria were cultured in groups of 5 repli-
cates in 30-mm dishes with 1.5 ml Biggers, Gwatkin, and Jenkins
medium (ICN Biomedicals, Inc., Thame, UK) containing 5%
heat-inactivated rabbit serum (GIBCO BRL, Paisley, UK) and 50
 
m
 
g/ml ascorbic acid (Sigma Chemical Co., Poole, UK). After 24 h
in culture, the media was replaced with media containing various
concentrations of sonicated Mt, r-Mt cpn10 or Mt cpn10 pep-
tides with or without a range of concentrations of mAb to Mt
cpn10 (SA12; reference 12), mAb to Mt cpn60 (TB78; reference
13), mAb to Mt LAM at 1:1,000 dilution. Calvaria were cultured
for a further 48 h and then the calcium released into the medium
was measured by automated colorimetric analysis (19).
After removal of the media supporting the calvarial explants for
calcium assay, the explants were then used for the measurement
of osteoclast numbers by a modification of the method of Mar-
shall et al. (20). The calvaria were fixed in 95% ethanol, 5% glacial
acetic acid for 24 h, and were then washed in PBS containing 1
mg/ml BSA followed by reaction in the histochemical substrate
mixture (obtained from Sigma Chemical Co., and used according
to the manufacturer’s instructions) for the localization of tartrate-
resistant acid phosphatase (TRAP) activity, a marker enzyme for
osteoclasts. Bones were then washed in PBS, decalcified, and
fixed in 12.5% glutaraldehyde (BDH Chemicals, Ltd., Poole,
UK) in 1 M hydrochloric acid (BDH Chemicals, Ltd.) for 5 min.
Finally, the bone explants were washed and mounted in Aqua-
mount (BDH Chemicals, Ltd.). Each calvarial explant was then
scanned by transmitted light microscopy and TRAP-positive cells
containing three or more nuclei were counted. The individual
counting the cells was unaware of the treatment to which each
explant had been exposed. Control cultures included unstimu-
lated calvaria (to determine spontaneous release of calcium) and
calvarial cultures stimulated with 1 
 
m
 
M prostaglandin (PG; to
demonstrate that bone is responsive and to give a measure of the
maximal response). r-Mt cpn10 and Mt cpn10 peptides were
tested in a minimum of three experiments and gave reproducible
results.
 
Osteoblast Proliferation.
 
The measurement of cell proliferation
was as previously described (21). In brief, the human osteoblast-like
cell line MG63 (CRL 1427; American Type Culture Collection,
Rockville, MD) was cultured at a density of 15,000 cells/well in
96-well plates and incubated overnight at 37
 
8
 
C in DMEM
(Gibco) plus 10% FCS (Sigma Chemical Co.) in 5% CO
 
2
 
/air.
The media were then removed and cells were washed twice with
sterile Hank’s solution (Sigma Chemical Co.). To measure anti-
proliferative activity, various concentrations of r-Mt cpn10 or
truncated peptides were added in DMEM containing 2% FCS, to
the MG 63 cells. Cells were incubated for 24 h at 37
 
8
 
C. During
the last 6 h of culture, 0.05 
 
m
 
Ci of [
 
3
 
H]thymidine (Amersham In-
ternational plc, Amersham, UK) was added to cells. The media
were then removed and the cells fixed in 5% trichloroacetic acid.
100 
 
m
 
l of 0.5 M NaOH was used to lyse cells, this being neutral-
ized by an equal volume of 0.5 M HCl. Radioactivity incorpo-
rated into nuclear DNA was measured by scintillation spectrome-
try. The cytotoxicity of the r-Mt cpn10 was determined by lactate
dehydrogenase release, measured by the CytoTox 96 nonradioac-
tive cytotoxicity assay (Promega, Heidelberg, Germany). Data has
been generated from a minimum of three separate experiments.
 
Homology Modeling of Mt cpn10.
 
The Mt cpn10 model was
generated by homology modeling of the Mt cpn10 sequence onto
the atomic coordinates of the GroES structure of the monomer
with the flexible loop assigned. The model was energy minimized
with QUANTA/CHARMm (Molecular Simulations, Inc., San
Diego, CA) using a nonbonded cutoff of 14 Å and a dielectric
constant distance dependence until the root mean squared devia-
tions were 
 
,
 
0.001 Kcal/Å. The side chains were minimized first,
keeping the backbone fixed. This was followed by minimization
of the whole monomer. The heptamer was generated from the
monomer by the symmetry operations relating the GroES subunits.
The same energy minimization procedure was repeated for the final
Mt cpn10 heptamer model, which was displayed with the SYBYL
molecular modeling package (Tripos UK, Milton Keynes, UK).
 
Results and Discussion
 
Sonicates of viable Mt added to explants of murine cal-
varial bone produced a dose-dependent stimulation of bone
resorption, measured as calcium release into the tissue cul-
ture medium. Osteoclast numbers in calvarial explants were 
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counted and showed a parallel increase (Fig. 1 
 
A
 
). The Mt
sonicate–induced stimulation of bone resorption was dose
dependently and completely inhibited by a neutralizing
mAb to Mt cpn10 (SA12; reference 12), but not by a sub-
class-matched neutralizing mAb to Mt cpn60 (TB78; refer-
ence 13). Likewise, the mAb SA12 caused a dose-depen-
dent decrease in the numbers of osteoclasts present in the
calvarial explants (Fig. 1 
 
B
 
). In contrast, SA12 had no effect
on the stimulation of bone resorption induced by PG (Fig.
1 
 
C
 
). Purified Mt LAM, added at a concentration of 1 
 
m
 
g/
ml, had no osteolytic activity, and neutralizing mAb to
LAM did not inhibit the bone resorption induced by the
Mt sonicate (results not shown). Addition of polymyxin B
had no effect on the bone resorbing activity of the Mt son-
icate.
Purified r-Mt cpn10 caused a dose-dependent stimula-
tion of calcium release from cultured calvaria with os-
teolytic activity being noted at a concentration of 1 ng/ml
(equivalent to 100 pmol) that was reproducible and statisti-
cally significant (
 
P
 
 
 
,
 
 0.01; Fig. 2 
 
A
 
). The bone resorbing
activity of Mt cpn10 was dose dependently and completely
inhibited by mAb SA12 (Fig. 2 
 
B
 
). The osteoclast-inacti-
vating hormone, calcitonin, at a concentration of 10 ng/ml,
also blocked r-Mt cpn10-induced bone resorption (results
not shown). Addition of polymyxin B had no effect on the
bone resorbing activity of r-Mt cpn10.
Addition of r-Mt cpn10 to subconfluent cultures of the
human osteoblast-like cell line MG63 caused significant inhi-
bition of cell proliferation at concentrations 
 
>
 
1 nM (Fig. 3).
Inhibition of proliferation was not due to cytotoxicity of
the r-Mt cpn10.
A panel of 11 NH
 
2
 
- and COOH-terminal truncated
peptides and short peptides (16) were used to define the
specific structural features of r-Mt cpn10 responsible for its
osteolytic and osteoblast antiproliferative activities. These
peptides corresponded to residues 1–25, 1–58, 26–99, 46–
99, 51–99, 54–99, 59–99, 65–99, 71–86, 75–99, and 91–99.
Graded concentrations of each peptide were tested sepa-
rately in each assay in three separate experiments. 2 of these
Figure 1. Effect of Mt sonicate on
bone resorption. (A) Release of cal-
cium from explants of murine calva-
ria and induction of osteoclast re-
cruitment in the calvaria by dilutions
of a sonicate of viable Mt. (B) The
effect of adding various concentra-
tions of mAb (12) SA12 (which rec-
ognizes Mt cpn10) or a mAb to Mt
cpn60 (13) to bone explants stimu-
lated with a fixed concentration of
Mt sonicate (3 mg/ml) on the release
of calcium from calvarial explants
and on the numbers of osteoclasts in
the calvaria. Controls with no Mt
cpn10 (unstimulated calvaria) and
with 1 mM PG are shown for comparison. (C) The effect of increasing concentrations of SA12 on the bone resorbing activity of PG. Results are ex-
pressed as the mean and standard deviation of five replicate cultures.
Figure 2. Effect of r-Mt
cpn10 on bone resorption. (A)
Dose-dependent stimulation of
calcium release from murine cal-
varial explants cultured in the
presence of purified r-Mt
cpn10. The filled column repre-
sents the calcium released from
bone explants cultured with 1
mM PG. (B) Effect of adding
graded concentrations of mAb
SA12 to calvarial bone explants
stimulated with 100 ng/ml r-Mt
cpn10. Results are expressed as
the mean and standard deviation
of five replicate cultures.
Figure 3. Mt cpn10–induced
inhibition of osteoblast prolifera-
tion. The effect of purified r-Mt
cpn10 on the proliferation of the
human osteoblast–like cell line
MG 63. Inhibition of prolifera-
tion is measured as the percent-
age of total inhibition (no thymi-
dine incorporation) calculated
from the percentage of decrease
in thymidine incorporation for a
control cell culture. 
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11 peptides, 26–99 and 65–99, exhibited reproducible os-
teolytic activity (Fig. 4). Polymyxin B had no inhibitory ef-
fects on the activity of these peptides. Peptide 26–99 con-
tains sequences that are within the flexible loop region of
Mt cpn10 (residues 16–35). To determine if this flexible loop
contributed to the osteolytic activity, two short peptides
within the flexible loop in Mt cpn10 (21–35: TTTASG-
LVIPDTAKE) and in the 
 
E. coli
 
 cpn10 (GroES residues
23–33: GGIVLTGSAAA) were synthesized and were also
found to have osteolytic activity in the calvarial assay (Fig.
4). Mt, unlike 
 
E. coli
 
, is able to secrete extracellular cpn10
(22), which has important implications for the pathogenic
effects of Mt cpn10 in vivo.
All 12 Mt cpn10 peptides were repeatedly tested for an-
tiproliferative activity but even at very high concentrations,
none showed any ability to inhibit osteoblast proliferation.
Peptide 1–58 was inactive in the bone resorption assay,
although it contains the predicted flexible loop. The most
likely explanation is that the structure of 1–58 differs from
that of whole protein, because peptide 1–58 is a dimer (16),
the aggregation of which is unusual as it occurs via the
NH
 
2
 
-terminal region in contrast to the whole protein in
which contact between two neighboring protomers in-
volves the COOH-terminal tail of one protomer and the
NH
 
2
 
-terminal region of the other (23).
Peptides 46–99, 51–99, 54–99, and 59–99 were also in-
active, although they contain the active 65–99 sequence,
and again, structural differences are the likely explanation
for this discrepancy. For example, the structure of the inac-
tive peptide 59–99 has been assigned to that of four anti-
parallel 
 
b
 
 strands (24), but circular dichroism spectroscopy
data with the active peptide 65–99 (data not shown) indi-
cate that the latter is mainly composed of the random coil
conformation. Peptide 26–99 is active in the bone resorp-
tion assay since most of the mobile loop is part of its NH
 
2
 
-
terminal tail and is probably accessible to solvent (and
hence a receptor) as often happens to the NH
 
2
 
-terminal
and COOH-terminal regions of polypeptides and proteins.
For the same reason, amino acids 65–70 would be consid-
ered the active sequence in peptide 65–99.
A molecular model of heptameric Mt cpn10 was derived
from the 
 
E. coli
 
 cpn10 crystal structure (reference 23; Fig. 5).
The sequences derived from the peptide data which con-
tribute to the osteolytic activity are colored red and corre-
spond to the flexible loop (21–35) at the bottom outer edge
of the heptamer which is in close proximity to the se-
quence 65–70. Although the flexible loop is exposed in the
heptameric model, the sequence 65–70 is inaccessible at
the subunit interface. Furthermore, based on studies with
GroES, which dissociates to monomers 
 
,
 
1 
 
m
 
M (25), Mt
cpn10 would be expected to dissociate at the concentra-
tions used in all these biological assays. This suggests that an
alternative oligomeric form of Mt cpn10 may be required
for osteolytic activity. A tetrameric form of Mt cpn10 has
been reported (16), and this may be the osteolytically active
form. Alternatively, Mt cpn10 might assemble as a hep-
Figure 4. Bone resorbing ac-
tivity of NH2- and COOH-ter-
minal truncated Mt cpn10 pep-
tides compared to full-length
Mt cpn10. The top graph shows
the amount of calcium released,
in one typical experiment, from
calvarial explants cultured with
r-Mt cpn10 or truncated syn-
thetic Mt cpn10 peptides at a
concentration of 1 mg/ml. The
bottom section shows the se-
quences of the various Mt cpn10
peptides and the sequences of Mt
and  E. coli cpn10. A peptide
GGIVLTGSAAA which spans
residues 23–33 in the mobile
loop of E. coli cpn10 also dem-
onstrated osteolytic activity
(shaded column). The background
release of calcium has been sub-
tracted. Results are expressed as
the mean and standard deviation
of five replicate cultures. 
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tamer only at the putative cell receptor. The flexible loop
also binds to cpn60 in the cpn60–cpn10 protein-folding
complex (26), suggesting that the putative cell receptor for
Mt cpn10 has some structural homology with cpn60. If this
structural homology is significant, it would require the Mt
cpn10 to assemble as a heptamer on the receptor. Consid-
ering the gross structural rearrangements that occur in the
cpn10 subunits of the heptamer when it binds to cpn60
(27), it may be possible for the two active sequences in Mt
cpn10 to make contact with the receptor. None of the
peptide fragments containing the active sequences appear
to be involved in the interaction of Mt cpn10 with the hu-
man osteoblast-like cell line MG63, possibly due to their
inability to assemble as a heptamer. In this regard, it may be
important to note that mitochondrial cpn60 is expressed on
the surface of human cells (28). These receptors are likely
to be of therapeutic importance in the treatment of bone
tuberculosis and possibly in other bone diseases.
Based upon the peptide activity data, the Mt cpn10
structure model gives an approximate guide to the location
of the osteolytically-active sequences on the Mt cpn10
structure. The precise molecular structure accounting for
the bioactivity of Mt cpn10 will be obtained by ongoing
work on solving the Mt cpn10 structure by x-ray crystal-
lography (Roberts, M.M., A. Coker, G. Fossati, P. Mas-
cagni, A.R.M. Coates, and S.P. Wood, unpublished data)
and the use of site-directed mutagenesis.
It is not known which Mt strains are associated with
Pott’s disease. In this study we have tested the Mt strain
H37Rv, which is a virulent strain commonly used in re-
search into tuberculosis. We have shown that the obligate
protein, Mt cpn10, is the osteolytically-active component
produced by this organism. All strains of Mt must contain
this protein and therefore have the potential to induce
bone disease. There may be additional factors to consider in
the propensity of Mt to cause Pott’s disease, and further
studies into this area are clearly necessary.
Figure 5. Locations of se-
quences on the Mt cpn10 struc-
ture that are likely to be impor-
tant in bone resorption. Stereo
view of polypeptide backbone of
Mt cpn10 heptamer model
viewed from the top down the
sevenfold axis with one subunit
highlighted in green. Peptide se-
quences with osteolytic activity
are highlighted in red.
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